Terms: = Breast cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
1249 results:
1. Cytoplasmic localization of SETDB1‑induced Warburg effect via c‑MYC‑LDHA axis enhances migration and invasion in breast carcinoma.
Yang W; Wei Y; Wang T; Xu Y; Jin X; Qian H; Yang S; He S
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426579
[TBL] [Abstract] [Full Text] [Related]
2. The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.
Poddar A; Ahmady F; Rao SR; Sharma R; Kannourakis G; Prithviraj P; Jayachandran A
J Biomed Sci; 2024 Feb; 31(1):23. PubMed ID: 38395880
[TBL] [Abstract] [Full Text] [Related]
3. Curcumin suppresses metastasis of triple-negative breast cancer cells by modulating emt signaling pathways: An integrated study of bioinformatics analysis.
Chen Z; Lu P; Li M; Zhang Q; He T; Gan L
Medicine (Baltimore); 2024 Feb; 103(8):e37264. PubMed ID: 38394486
[TBL] [Abstract] [Full Text] [Related]
4. Estrogen-related receptor alpha (ERRα) promotes the migration, invasion and angiogenesis of breast cancer stem cell-like cells.
Muduli K; Pradhan J; Prusty M; Samal AP; Reddy KS; Elangovan S
Med Oncol; 2024 Feb; 41(3):78. PubMed ID: 38393411
[TBL] [Abstract] [Full Text] [Related]
5. Characterization of a germline variant TNS1 c.2999-1G > C in a hereditary cancer syndrome family.
Di X; Wang D; Wu J; Zhu X; Wang Y; Yan J; Wen L; Jiang H; Wen D; Shu B; Zhang S
Gene; 2024 May; 908():148304. PubMed ID: 38387708
[TBL] [Abstract] [Full Text] [Related]
6. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway.
Takeda T; Tsubaki M; Genno S; Tomita K; Nishida S
Exp Cell Res; 2024 Mar; 436(2):113978. PubMed ID: 38382805
[TBL] [Abstract] [Full Text] [Related]
7. Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis.
Deng L; Wang J; Song J; Wu Q; Gong Z; Song J; Hou L
Sci Rep; 2024 Feb; 14(1):3265. PubMed ID: 38331968
[TBL] [Abstract] [Full Text] [Related]
8. Deciphering the oncogenic landscape: Unveiling the molecular machinery and clinical significance of LncRNA TMPO-AS1 in human cancers.
Saraswat SK; Mahmood BS; Ajila F; Kareem DS; Alwan M; Athab ZH; Shaier JB; Hosseinifard SR
Pathol Res Pract; 2024 Mar; 255():155190. PubMed ID: 38330619
[TBL] [Abstract] [Full Text] [Related]
9. The Use of Schisandrin B to Combat Triple-Negative breast cancers by Inhibiting NLRP3-Induced Interleukin-1β Production.
Chang CM; Liang TR; Lam HYP
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254674
[TBL] [Abstract] [Full Text] [Related]
10. Secretomics reveals hormone-therapy of breast cancer may induce survival by facilitating hypercoagulation and immunomodulation in vitro.
Augustine TN; Buthelezi S; Pather K; Xulu KR; Stoychev S
Sci Rep; 2024 Jan; 14(1):1486. PubMed ID: 38233507
[TBL] [Abstract] [Full Text] [Related]
11. Isolation of Viable Epithelial and Mesenchymal Circulating Tumor Cells from breast cancer Patients.
Topa J; Żaczek AJ; Markiewicz A
Methods Mol Biol; 2024; 2752():43-52. PubMed ID: 38194026
[TBL] [Abstract] [Full Text] [Related]
12. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
13. Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
Terragno M; Vetrova A; Semenov O; Sayan AE; Kriajevska M; Tulchinsky E
Sci Rep; 2024 Jan; 14(1):425. PubMed ID: 38172210
[TBL] [Abstract] [Full Text] [Related]
14. PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy.
Lyu L; Li H; Lu K; Jiang S; Li H
Br J Cancer; 2024 Feb; 130(3):394-405. PubMed ID: 38110664
[TBL] [Abstract] [Full Text] [Related]
15. GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transition.
Li M; Wang X; Chen X; Hong J; Du Y; Song D
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166925. PubMed ID: 38084873
[TBL] [Abstract] [Full Text] [Related]
16. Manipulating macrophage polarization with nanoparticles to control metastatic behavior in heterotypic breast cancer micro-tissues
Sungu M; Isik M; Güler Ü; Eylem CC; Eskizengin H; Nemutlu E; Salih B; Derkus B
Nanoscale; 2023 Dec; 16(1):394-410. PubMed ID: 38073471
[TBL] [Abstract] [Full Text] [Related]
17.
Zavareh VA; Gharibi S; Hosseini Rizi M; Nekookar A; Mirhendi H; Rahimmalek M; Szumny A
Cells; 2023 Nov; 12(23):. PubMed ID: 38067141
[TBL] [Abstract] [Full Text] [Related]
18. CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway.
Li F; Wang J; Yan YQ; Bai CZ; Guo JQ
BMC Cancer; 2023 Dec; 23(1):1214. PubMed ID: 38066486
[TBL] [Abstract] [Full Text] [Related]
19. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (emt).
Tangsiri M; Hheidari A; Liaghat M; Razlansari M; Ebrahimi N; Akbari A; Varnosfaderani SMN; Maleki-Sheikhabadi F; Norouzi A; Bakhtiyari M; Zalpoor H; Nabi-Afjadi M; Rahdar A
Biomed Pharmacother; 2024 Jan; 170():115973. PubMed ID: 38064969
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear isoform of RAPH1 interacts with FOXQ1 to promote aggressiveness and radioresistance in breast cancer.
Liu Q; Cao Y; Wei X; Dong H; Cui M; Guan S; Liu B; Wang X; Xing P
Cell Death Dis; 2023 Dec; 14(12):803. PubMed ID: 38062011
[TBL] [Abstract] [Full Text] [Related]
[Next]